Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily dose-ranging study of GSK189075 versus placebo in treatment-naïve type 2 diabetes mellitus
2007-001463-29Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remogliflozin etabonate in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by GSK. Primary endpoint: Change from baseline in HbA1c at Week 12 (once-daily GSK189075 vs placebo). Started Jun 2007; status: completed.
02
Drugs
remogliflozin etabonate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-001463-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001463-29.